Prospects for Cure | Patrick Kennedy

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

State-of-the-art treatment of Hepatitis B | Cihan Yurdaydin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Panel discussion Session 1

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Russia | Vadim Rassokhin, MD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Turkey | Serhat Unal, MD (Presented by Cihan Jurdaydin)

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Georgia | Akaki Abutidze, MD, MPH, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Czech and Slovak Republics | Viktor Aster, MD, PHD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Poland | Miłosz Parczewski, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Slovenia and the Balcan countries | Mojca Maticic, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in the Baltic countries | Saulius Caplinskas, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Ukraine | Pavlo Skala

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Local situation in Romania | Oana Săndulescu, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and HIV 2016

Session 7 Discussion

European Meeting on HIV & Hepatitis 2016

Improving PI drug resistance scores | Jens Verheyen, MD, PhD

European Meeting on HIV & Hepatitis 2016

PI remain important options for first line | Linos Vandekerckhove, MD, PhD

European Meeting on HIV & Hepatitis 2016

Session 5 Discussion

European Meeting on HIV & Hepatitis 2016

Maintenance Therapy - What is the scientific/ virological rational | Charles Boucher, MD, PhD

European Meeting on HIV & Hepatitis 2016

HIV attachment Inhibitors - Educational lecture in collaboration with ESAR | Thomas Klimkait, MD

European Meeting on HIV & Hepatitis 2016

Session 4 Discussion

European Meeting on HIV & Hepatitis 2016

Community perspective | Rebekah Webb

European Meeting on HIV & Hepatitis 2016

Roadblocks to implementation | Pep Coll, MD

European Meeting on HIV & Hepatitis 2016

HIV in Europe 2020 – what will it look like? | Carlo Federico Perno, MD, PhD

European Meeting on HIV & Hepatitis 2016

Regulatory landscape for NASH | Veronica Miller

HEP DART 2017

Aramchol for NASH and beyond: From scientific rationale to clinical development | Carol Brosgart

HEP DART 2017